Trudeau’s science adviser preparing report on COVID-19 vaccine passports Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer People in a Tel Aviv audience wear protective face masks during a performance by Israeli musician Ivri Lider at a soccer stadium on March. 5, 2021. All guests were required to show a Green Pass for proof of COVID-19 vaccination or full recovery from the virus, a tool Canadian authorities are also considering. Oded Balilty/The Associated Press
(1) The phase IIa proof-of-concept findings from ViiV Healthcare s innovative early pipeline of medicines show the antiviral activity, safety and tolerability of GSK 254 and support its continued study in phase IIb ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, presented positive data from its phase IIa proof-of-concept study of the investigational maturation inhibitor GSK3640254 (GSK 254). The study showed the antiviral activity of GSK 254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. These findings were presented today at the (virtual) 2021 Conference on Retroviruses and Opportunistic Infections (CROI).
Sheikha Latifa bint Mohammed Al Maktoum speaking into a mobile phone camera. Picture credit (AP) GENEVA: The United Nations said on Friday it was yet to see evidence from the United Arab Emirates government that Dubai s Sheikha Latifa was still alive. The UN rights office had asked to see proof that the daughter of Dubai ruler Sheikh Mohammed bin Rashid Al-Maktoum was still alive, but when asked if it had been received, spokesman Rupert Colville told reporters: Not yet, no. FacebookTwitterLinkedinEMail